Binds A Virus Or Component Or Product Thereof (e.g., Virus Associated Antigen, Etc.) Patents (Class 435/339)
  • Patent number: 10113151
    Abstract: A composition is provided which comprises a recombinant viral particle comprising a capsid, wherein the viral particle is encapsulated into an anionic liposome comprising lecithin and polyethylene glycol (PEG). A method for preparing and purifying the encapsulated viral particles is provided as well. Methods for treating patients by using the encapsulated viral particles are provided as well.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: October 30, 2018
    Assignee: The Regents of the University of California
    Inventors: Andrew C. Kummel, Sarah L. Blair, Tony R. Reid, William C. Trogler, Farah Hedjran, Natalie Mendez, Vanessa Herrera
  • Patent number: 10004796
    Abstract: The present invention relates to a recombinant adenoviral vector for generating immunity against enterovirus infection. In one embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a PI protein and a 3 CD protease of an enterovirus. In another embodiment, the recombinant adenoviral vector of the invention comprises an expression cassette encoding a 3C protease or a 3CD protease of an enterovirus. The present invention also relates to a vaccine composition comprising the recombinant adenoviral vector as described. A method of inducing an immune response in a subject against enterovirus infection using the recombinant adenoviral vector and the vaccine composition is provided. Further provided is a method for producing virus like particles of an enterovirus by expressing the adenoviral vector as described herein in mammalian cells.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: June 26, 2018
    Assignee: National Health Research Institutes
    Inventors: Yen-Hung Chow, Yueh-Liang Tsou, Pele Choi-Sing Chong
  • Patent number: 9063150
    Abstract: Disclosed herein is a rapid and universal assay for the detection of antigen-specific antibodies in biological samples. The assay allows for the detection of antigen-specific antibodies in any species, including species for which secondary antibodies or antisera have not been developed or are not available. Biological samples to be tested are directly labeled, such as with biotin, and contacted with antigen-bound microparticles. The presence of antigen-specific antibodies in the biological samples is detected using a binding partner for the label, such as a biotin binding partner, conjugated to a detectable label, such as a fluorophore. This improved test provides a total antibody assay that is capable of detecting all classes of antibodies simultaneously.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: June 23, 2015
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control Prevention
    Inventor: Alison Jane Basile
  • Patent number: 8992929
    Abstract: The present invention relates to the murine monoclonal antibody 4C2 or to chimeric or humanized monoclonal antibodies specific to a major neutralizing epitope of influenza H5 hemagglutinin and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using such murine or chimeric or humanized monoclonal antibodies or fragments thereof.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: March 31, 2015
    Assignee: Temasek Life Sciences Laboratory Limited
    Inventors: Prabakaran Mookkan, Fang He, Hwei-Sing Jimmy Kwang
  • Publication number: 20150086973
    Abstract: A monoclonal antibody against the Duck Tembusu virus and a hybridoma cell line secreting the monoclonal antibody, a reagent kit and method for detecting a Duck Tembusu virus antibody, and application of the monoclonal antibody in preparing products for diagnosing the Duck Tembusu virus disease. The monoclonal antibody may bind specifically to E protein of Duck Tembusu virus and has an activity of neutralizing Duck Tembusu virus.
    Type: Application
    Filed: May 16, 2012
    Publication date: March 26, 2015
    Applicant: SHANGHAI VETERINARY RESEARCH INSTITUTE, CAAS
    Inventors: Zejun Li, Xuesong Li
  • Publication number: 20150044225
    Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.
    Type: Application
    Filed: October 3, 2014
    Publication date: February 12, 2015
    Inventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
  • Publication number: 20150037352
    Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
  • Publication number: 20150010566
    Abstract: The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza A virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza A virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza A virus infection.
    Type: Application
    Filed: December 3, 2012
    Publication date: January 8, 2015
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Arjen Quirinus Bakker
  • Publication number: 20140377279
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: December 25, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Publication number: 20140341923
    Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
    Type: Application
    Filed: August 1, 2014
    Publication date: November 20, 2014
    Inventor: Po-Ying Chan-Hui
  • Publication number: 20140342349
    Abstract: A protein complex isolated from its natural medium and including the ZEBRA protein of sequence SEQ ID NO: 1, the isolated protein complex having the following properties: it is more stable than the ZEBRA protein, in particular it is more resistant to the action of the proteases than the ZEBRA protein, it is capable of specifically binding the AZ125 and AZ130 monoclonal antibodies, it is soluble in a body fluid, and in particular a body fluid selected from the group constituted by blood and serum, and to its detection process and the uses of this process for the prognosis or diagnosis of lymphoproliferative episodes associated with the EBV.
    Type: Application
    Filed: December 4, 2012
    Publication date: November 20, 2014
    Applicant: UNIVERSITE JOSEPH FOURIER
    Inventors: Emmanuel Drouet, Mohammed Habib, Felix Agbalika
  • Publication number: 20140328797
    Abstract: The invention provides isolated fully human monoclonal anti-HRV antibodies, as well as method of making and using these antibodies. Anti-HRV antibodies of the invention prevent or treat subjects having HRV-infections, and related diseases, including, but not limited to, the common cold, nasopharyngitis, croup, pneumonia, bronchiolitis, asthma, chronic obstructive pulmonary disease (COPD), sinusitis, bacterial superinfection, and cystic fibrosis.
    Type: Application
    Filed: April 28, 2014
    Publication date: November 6, 2014
    Inventors: Po-Ying Chan-Hui, III, Kristine Swiderek
  • Publication number: 20140322210
    Abstract: Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza.
    Type: Application
    Filed: December 5, 2012
    Publication date: October 30, 2014
    Inventors: Lawrence M. Kauvar, Stote Ellsworth, William Usinger, Krista Maureen McCutcheon, Minha Park
  • Patent number: 8871207
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 28, 2014
    Assignee: Humabs, LLC
    Inventor: Antonio Lanzavecchia
  • Patent number: 8865479
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: October 21, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8858947
    Abstract: The present invention provides identification and characterization of conformational epitopes of the envelope protein E2 of the Hepatitis C virus (HCV). The present invention provides a panel of human monoclonal antibodies that recognize conformational epitopes of E2. The antibodies are derived from patients infected with HCV. The present invention provides methods for utilizing HCV antibodies as therapeutic, diagnostic, and/or prophylactic agents. The present invention provides mimotopes with conformational epitopes intact and methods of using mimotopes. The present invention provides methods of stratifying patients based on their response to HCV. The present invention provides pharmaceutical compositions for prevention and treatment of HCV comprising one or more HCV antibodies.
    Type: Grant
    Filed: October 5, 2008
    Date of Patent: October 14, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Steven Foung, Zhen-yong Keck
  • Publication number: 20140302598
    Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.
    Type: Application
    Filed: May 21, 2014
    Publication date: October 9, 2014
    Inventors: Se-Ho KIM, Ki Hwan CHANG, Kwang-Won HONG, Yong-Won SHIN, Min-soo KIM, Hae-Won LEE, Kyung Hwan RYOO, Dong Hyuck SEO, Jean Man KIM, Yong Nam SHIN, Sunmi KOO, Jung-Ae LIM, Mijung LEE, Yeon Kyung LEE, Misun SEO
  • Publication number: 20140275492
    Abstract: The present invention provides for methods of producing human monoclonal antibodies against a wide variety of antigens including bacterial and viral antigens, as well as tumor antigens, and various autoantigens. Also provided are the antibodies themselves, nucleic acids encoding such antibodies, cells producing such antibodies, and methods of using such antibodies for diagnostic assays and passive immunity against disease states such as infection and cancer.
    Type: Application
    Filed: March 12, 2014
    Publication date: September 18, 2014
    Applicant: MUSC Foundation for Research Development
    Inventors: Natalie SUTKOWSKI, Semyon Rubinchik
  • Publication number: 20140271653
    Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicant: Regeneron Pharmaceuticals, Inc.
    Inventors: Anne Gurnett-Bander, David Perez-Caballero, Sumathi Sivapalasingam, Xunbao Duan, Douglas MacDonald
  • Patent number: 8835188
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 16, 2014
    Assignee: Presidents and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8835187
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 16, 2014
    Assignee: Presidents and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Patent number: 8828400
    Abstract: Described is an antibody or an antigen binding fragment thereof specifically binding to a full or empty H-1 parvovirus capsid. Such an antibody is useful for various diagnostic and therapeutic methods, e.g., for the detection/therapy of an H-1 parvovirus infection during pregnancy since parvovirus affects about 1 in 400 pregnancies and may cause fetal loss or fetal hydrops.
    Type: Grant
    Filed: December 1, 2010
    Date of Patent: September 9, 2014
    Assignee: Deutsches Krebsforschungszentrum Siftung des Öffentlichen Rechts
    Inventors: Barbara Leuchs, Kathrin Kürschner, Andrea Kuck, Marcus Müller, Silvia Münstermann, Jean Rommelaere
  • Patent number: 8828399
    Abstract: Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: September 9, 2014
    Assignee: The Trustees of Princeton University
    Inventors: Thomas Shenk, Dai Wang
  • Publication number: 20140234336
    Abstract: The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.
    Type: Application
    Filed: September 27, 2012
    Publication date: August 21, 2014
    Inventors: Shin Jae Chang, Ki Sung Kwon, Kye Sook Yi, Hyun Joo Lee, Jae Won Jeon, Hwang Keun Jun, Min Seok Chang
  • Patent number: 8795667
    Abstract: The present invention relates to improved compositions for the prevention and treatment of smallpox, and in particular to the use of compositions containing an antibody that binds to an epitope found on the MV form of the smallpox virus and an antibody that binds to an epitope found on the EV form of the smallpox virus. The invention relates to such compositions, especially to non-blood derived antibody compositions, such as chimeric or humanized antibodies, and to methods for their use in imparting passive immunity against smallpox infection to individuals at risk of smallpox virus infection or who exhibit smallpox.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: August 5, 2014
    Assignee: MacroGenics, Inc.
    Inventors: Leslie S. Johnson, Ling Huang
  • Patent number: 8772049
    Abstract: Screening assays and methods of performing such assays are provided. In certain examples, the assays and methods may be designed to determine whether or not two or more species can associate with each other. In some examples, the assays and methods may be used to determine if a known antigen binds to an unknown monoclonal antibody.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: July 8, 2014
    Assignee: President and Fellows of Harvard College
    Inventors: J. Christopher Love, Hidde L. Ploegh, Jehnna Ronan
  • Publication number: 20140178405
    Abstract: Monomeric VHH domain derived from anti-VP6 camelid antibodies, dimeric domain, immunisation method, rotavirus detection method, vaccine composition, prevention and treatment methods for rotavirus infections, wherein said domain may be any of the amino acid sequences shown in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 or SEQ ID No. 4, and wherein said domains bind to protein VP6 of Group A rotavirus.
    Type: Application
    Filed: December 3, 2013
    Publication date: June 26, 2014
    Applicant: Instituto Nacional De Tecnologia Agropecuaria (Inta)
    Inventors: Thomas SURREY, Aurelien OLICHON, Lorena Laura GARAICOEACHEA, Gisela Ariana MARCOPPIDO, Gladys Viviana PARREÑO, Silvia GÓMEZ SEBASTIÁN, José Angel MARTÍNEZ ESCRIBANO, Andrés WIGDOROVITZ
  • Publication number: 20140170163
    Abstract: Provided herein are methods of producing neutralizing monoclonal antibodies, by cyclical immunization, that cross-react with strains of Influenza virus of the same subtype or different subtypes. Also provided herein are compositions comprising such antibodies and methods of using such antibodies to diagnose, prevent or treat Influenza virus disease.
    Type: Application
    Filed: January 23, 2014
    Publication date: June 19, 2014
    Applicant: MOUNT SINAI SCHOOL OF MEDICINE
    Inventors: Adolfo Garcia-Sastre, Peter Palese, Taia T. Wang
  • Publication number: 20140162357
    Abstract: This invention generally relates to methods for the production of antibody producing cells and antibodies in protooncogene expressing animals. The invention also relates to methods for the efficient production of antibodies specific for antigens that are normally subject to immunological constraints such as self tolerance. The invention further relates to the production of antibody producing cells and antibodies without the need for the conventional fusing of antibody producing B cells with a myeloma fusion partner.
    Type: Application
    Filed: September 4, 2013
    Publication date: June 12, 2014
    Applicant: NATIONAL JEWISH HEALTH
    Inventors: Yosef Refaeli, Brian C. Turner
  • Publication number: 20140161822
    Abstract: The present invention provides anti-hemagglutinin antibodies, compositions comprising anti-hemagglutinin antibodies, and methods of using the same.
    Type: Application
    Filed: November 12, 2013
    Publication date: June 12, 2014
    Applicant: Genentech, Inc.
    Inventors: Min XU, Mercedesz BALAZS, Ning CHAI, Nancy Chiang, Henry CHIU, Zhaoyu JIN, Zhonghua LIN, Patrick LUPARDUS, Gerald R. NAKAMURA, Hyunjoo PARK, Lee SWEM
  • Publication number: 20140093500
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided.
    Type: Application
    Filed: September 27, 2013
    Publication date: April 3, 2014
    Applicant: MEDIMMUNE LIMITED
    Inventors: Tim Beaumont, Adrianus Q. Bakker, Etsuko Yasuda
  • Publication number: 20140072575
    Abstract: The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 13, 2014
    Applicant: MedImmune Limited
    Inventors: Hergen Spits, Tim Beaumont, Mark Jeroen Kwakkenbos, Etsuko Yasuda
  • Patent number: 8669047
    Abstract: The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.
    Type: Grant
    Filed: July 21, 2011
    Date of Patent: March 11, 2014
    Assignee: Theranos, Inc.
    Inventors: Elizabeth A. Holmes, Ian Gibbons
  • Publication number: 20140065166
    Abstract: The invention described herein provides novel peptides. The novel peptides are useful alone or as portions of larger molecules, such as antibodies or antibody fragments, that can be used to treat or prevent infection of Nipah virus and/or Hendra virus.
    Type: Application
    Filed: April 9, 2013
    Publication date: March 6, 2014
    Applicant: The Henry M. Jackson Foundation for the Advancemen t of Military Medicine, Inc.
    Inventors: Christopher C. Broder, Deborah L. Fusco, Kai Hu, Dimitar B. Nikolov
  • Publication number: 20140044719
    Abstract: Provided herein are antibodies or antigen-binding fragments thereof that immunospecifically bind to the fusion (F) protein of Respiratory Syncytial Virus (RSV). Also provided are methods for of prevention, treatment and diagnosis of viral infection and/or the treatment of one more symptoms of RSV-mediated disease. Methods of generating antibodies that immunospecifically bind RSV F protein also are provided.
    Type: Application
    Filed: September 10, 2013
    Publication date: February 13, 2014
    Applicant: Crucell Holland B.V.
    Inventors: Robert Anthony Williamson, Jehangir Wadia, Gabriel Pascual, Elissa Koegh
  • Publication number: 20140046034
    Abstract: An object of the present invention is to provide an antibody inhibiting infection with hepatitis C virus (HCV). The present invention provides an anti-hepatitis C virus antibody that recognizes a whole or a part of the conformation of a hepatitis C virus particle as an epitope and binds thereto, so as to be able to inhibit the binding of hepatitis C virus to the surface of a host cell and to inhibit HCV infection, a humanized antibody thereof, and an inhibitory agent for infection with hepatitis C virus.
    Type: Application
    Filed: October 22, 2013
    Publication date: February 13, 2014
    Applicants: Japan as Represented by Director-General of National Institute of Infectious Diseases, TORAY INDUSTRIES, INC.
    Inventors: Takaji WAKITA, Kazumi NISHIMURA, Noriko NAKAMURA, Daisuke AKAZAWA
  • Patent number: 8647818
    Abstract: Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: February 11, 2014
    Assignees: UAB Research Foundation, University of Alabama—Birmingham, The United States of America, as represented by the Secretary, Department of Health and Human Services (Hereinafter the Government) Office of Technology Transfer, National Institutes of Health
    Inventors: George M. Shaw, Beatrice H. Hahn, Frederic Bibollet-Ruche, Peter D. Kwong
  • Publication number: 20140037648
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both RSV, MPV and PVM. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to polypeptides that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV or MPV infection and RSV and MPV co-infection.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 6, 2014
    Applicant: HUMABS BIOMED SA
    Inventor: HUMABS BIOMED SA
  • Patent number: 8637234
    Abstract: Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.
    Type: Grant
    Filed: April 8, 2005
    Date of Patent: January 28, 2014
    Assignees: UAB Research Foundation, The Administrators of Tulane Educational Fund, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: George M. Shaw, James E. Robinson, Frederic Bibollet-Ruche, Julie M. Decker, Beatrice H. Hahn, Peter D. Kwong
  • Patent number: 8628772
    Abstract: The invention relates to sequences of a novel variant of the Hepatitis B surface antigen (HBsAg) and to methods for detecting, in patient samples, nucleic acids, antigens, and antibodies directed against the same.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: January 14, 2014
    Assignee: Siemens Healthcare Diagnostics Products GmbH
    Inventor: Udo Krupka
  • Patent number: 8623595
    Abstract: Azido-diarylpyrimidine (azido-DAPY) compounds, and compositions containing such compounds, are provided. In addition, methods of using azido-diarylpyrimidines to inactivate reverse transcriptases, prepare inactivated viruses, and treat or prevent viral infections are also provided.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: January 7, 2014
    Assignee: Photoimmune Biotechnology Inc.
    Inventor: Adan Rios
  • Patent number: 8603467
    Abstract: The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody.
    Type: Grant
    Filed: June 16, 2008
    Date of Patent: December 10, 2013
    Assignees: Xiamen University, Yang Sheng Tang Company
    Inventors: Yixin Chen, Wenxin Luo, Jun Zhang, Ningshao Xia, Yi Guan, Honglin Chen
  • Patent number: 8592554
    Abstract: The present invention relates to the field of cytomegalovirus (CMV) infection. In particular the present invention relates to highly specific immunotoxins useful in treating diseases related to CMV infection. CMV encodes chemokine receptors that undergo constitutive internalization. Thus CMV infected cells can be targeted specifically with immunotoxins with high affinity to CMV encoded constitutively internalizing receptors. This will ensure efficient uptake of the immunotoxin by the CMV infected cell, and thereby ensure the death of the infected cell with a minimum of unwanted toxicity and side effects. Furthermore, the invention relates to a way of inhibiting CMV replication and/or growth by using immunotoxins by targeting constitutively internalizing CMV encoded receptors.
    Type: Grant
    Filed: July 3, 2007
    Date of Patent: November 26, 2013
    Assignee: Inagen ApS
    Inventors: Thomas Nitschke Kledal, Mette M. R. Roed
  • Publication number: 20130309248
    Abstract: Described are binding molecules, e.g., human monoclonal antibodies, that bind to influenza virus comprising HA of the H3 subtype, e.g., H3N2, and have a broad neutralizing activity against such influenza virus. Described are polynucleotides encoding the binding molecules, their sequences and compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules can be used in the diagnosis, prophylaxis, and/or treatment of influenza virus H3N2 infection. The binding molecules may provide cross-subtype protection, such that infections with H3, H7, and/or H10-based influenza subtypes can be prevented and/or treated.
    Type: Application
    Filed: May 20, 2013
    Publication date: November 21, 2013
    Inventors: Mark Throsby, Robert H.E. Friesen, Theodorus H.J. Kwaks, Mandy A. C. Jongeneelen
  • Publication number: 20130302349
    Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 14, 2013
    Applicant: Visterra, Inc.
    Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
  • Publication number: 20130302348
    Abstract: The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 14, 2013
    Applicant: Massachusetts Institute of Technology
    Inventors: S. Raguram, Viswanathan Sasisekharan, Venkataramanan Soundararajan, Ram Sasisekharan, Vidya Subramanian, Kannan Tharakaraman
  • Patent number: 8574581
    Abstract: Monoclonal antibodies and related binding proteins that bind specifically to the envelope glycoprotein of H5 subtypes or neuraminidase glycoprotein of N1 subtypes of avian influenza virus (AIV) are provided. The monoclonal antibodies and related binding proteins are useful for the detection of H5 and N1 subtypes of AIV, including H5N1 subtypes and provide means for the diagnosis, surveillance and treatment of dangerous viral infections.
    Type: Grant
    Filed: September 11, 2012
    Date of Patent: November 5, 2013
    Assignee: Temasek Life Sciences Laboratory Limited
    Inventors: Hong Liang Qian, Fang He, Hwei-Sing Kwang
  • Publication number: 20130259871
    Abstract: Compositions and methods for the treatment or prevention of Dengue virus infection in a vertebrate subject are provided. In particular, human neutralizing monoclonal antibodies to Dengue virus isolated from EBV immortalized B cells derived from patients who have recovered from Dengue infection are disclosed. Methods are provided for administering such antibodies to a vertebrate subject in an amount effective to reduce, eliminate, or prevent relapse from infection.
    Type: Application
    Filed: December 14, 2011
    Publication date: October 3, 2013
    Applicants: DSO NATIONAL LABORATORIES, NATIONAL UNIVERSITY OF SINGAPORE
    Inventors: Paul Anthony Macary, Ee Ping Evelyn Teoh, Brendon John Hanson, En Wei Teo, Angeline Pei Chiew Lim, Mah Lee Mary Ng, Shee Mei Lok, Petra Eveliina Kukkaro
  • Publication number: 20130189279
    Abstract: The invention relates to binding molecules against Chikungunya virus, which are able of neutralizing Chikungunya virus infectivity, and which can be used with therapeutic, diagnosis or research purposes, as well as to a pharmaceutical composition comprising said binding molecules.
    Type: Application
    Filed: April 7, 2011
    Publication date: July 25, 2013
    Applicant: Agency for Science, Technology and Research
    Inventors: Lucile Warter, Jean-Pierre Abastado, Alessandra Nardin, Cheng-I Wang
  • Publication number: 20130171169
    Abstract: The invention relates to neutralizing antibodies and antibody fragments having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for a combination of hCMV proteins UL130 and UL131A, or for a combination of hCMV proteins UL128, UL130 and UL131A. The invention relates also to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis and therapy of disease.
    Type: Application
    Filed: September 14, 2012
    Publication date: July 4, 2013
    Applicant: INSTITUTE FOR RESEARCH IN BIOMEDICINE
    Inventors: Antonio LANZAVECCHIA, Annalisa MACAGNO